Both companies are part of the biotechnology industry, which is not surprising, taking into account that investing in biotech stocks has proven to be a very profitable approach so far. However, if the biotech bubble is about to burst (according to many experts of late), Amici’s holdings in both United Therapeutics Corporation (NASDAQ:UTHR) and BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) don’t bear a lot of risk, since they only amass around 12% of the equity portfolio. Moreover, United Therapeutics Corporation (NASDAQ:UTHR), with a market cap of $8.1 billion, has a solid track record of revenue and earnings growth over the last several years. Another shareholder of the company is William Leland Edwards’ Palo Alto Investors, which owns 1.40 million shares as of the end of 2014.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)’s stock meanwhile has been gaining ground not only on the back of the company’s performance, but also amid many takeover rumors. Last year Switzerland-based Roche was mentioned as a possible buyer, while last week Shire PLC (ADR) (NASDAQ:SHPG) appeared on the Street’s radars as a party that might be interested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). However, so far all these rumors seem to be unfounded, and investors have been piling up capital into the company. One of the more bullish investors is Julian and Felix Baker‘s Baker Bros. Advisors, which added 1.34 million shares to its position during the last three months of 2014 and owns 3.71 million shares according to its latest 13F filing.
On the third spot in Amici Capital’s equity portfolio is Assured Guaranty Ltd. (NYSE:AGO), in which the investor holds close to 3.48 million shares, valued at $90.38 million. Biomarin and Assured Guaranty are two of the fund’s long-term picks and over the last years the investor has benefited from strong growth of both stocks. Assured Guaranty Ltd. (NYSE:AGO) is a small-cap insurance company engaged in providing credit protection products for the public finance and structured finance markets. The company has a ‘Buy’ consensus rating and a target price of $33 per share, which is approximately a 28% premium over the current price. Among the funds that we track, Amici owns the second-largest long position in Assured Guaranty Ltd. (NYSE:AGO), trailing Debra Fine’s Fine Capital Partners, which holds 5.61 million shares.